Research programme: proto oncogene protein c-myc inhibitors - Peptomyc

Drug Profile

Research programme: proto oncogene protein c-myc inhibitors - Peptomyc

Alternative Names: OMO-101; OMO-103; Omomyc-based cell penetrating peptides - Peptomyc; Omomyc-CPP

Latest Information Update: 11 May 2017

Price : *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator Peptomyc; Vall d-Hebron Research Institute
  • Class Antineoplastics; Peptides
  • Mechanism of Action Proto oncogene protein c-myc inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity No
  • Available For Licensing Yes

Highest Development Phases

  • Preclinical Cancer

Most Recent Events

  • 11 May 2017 Research programme: proto oncogene protein c-myc inhibitors - Peptomyc is available for licensing as of 11 May 2017. http://www.peptomyc.com/
  • 11 May 2017 Peptomyc plans a phase I/II trial in Glioblastoma (Peptomyc pipeline, May 2017)
  • 01 Jan 2016 Preclinical trials in Cancer in Spain (Intranasal)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top